Agilent Technologies Inc vs Five9 Inc — how do they compare? Agilent Technologies Inc trades at $147.76 (market cap $42.22B), while Five9 Inc trades at $31.22 (market cap $2.44B). The key difference: Agilent Technologies Inc is far larger — about 17.3× Five9 Inc's market cap, and Agilent Technologies Inc pays a 0.68% dividend while Five9 Inc pays none. Which is the better fit depends on your goals.
| A | FIVN | |
|---|---|---|
Market Cap | $42.22B | $2.44B |
Sector | Health | Technology |
52-Week High | $157.20 | $34.48 |
52-Week Low | $110.24 | $13.61 |
Enterprise Value | $43.77B | $2.59B |
Dividend Yield | 0.68% | — |
Signals from Pluang's Aura AI — not financial advice
Agilent Technologies (A) trades at $148.23, near its consensus price target of $154.90, with a slight 0.33% decline over 24 hours. The stock shows strong fundamentals, including a 19.55% net income margin and robust ROE of 21.33%, while technical indicators signal a bullish trend despite overbought RSI levels. Recent developments include FDA and EU approvals for diagnostic assays and the acquisition of Biocare Medical, reinforcing growth in biopharma services.
Outlook remains positive with 77.5% analyst buy ratings, but risks include high valuation multiples (P/E 30.02) and dependence on healthcare spending. Earnings beat in Q1 2026 supports upside, though Q2 2026 results due August 26 are critical for momentum. Institutional accumulation, like Ashton Thomas Securities' 47.1% stake increase in Q2 2026, underscores confidence.
Five9 (FIVN) trades at $31.14, down 9.69% today but remains near its 52-week highs. The stock shows strong technical momentum with bullish moving averages and has consistently beaten earnings estimates in recent quarters. Revenue growth accelerated to 10% in Q2 2026, reaching $312.4 million, while the company maintains a solid gross margin of 54.91%. Recent management appointments and AI-driven subscription growth provide positive catalysts.
The outlook remains positive with 61% analyst buy ratings and a $32.67 consensus target offering 5% upside. However, elevated valuation multiples (P/E 47.99) and ongoing fiduciary investigations pose risks. The stock's trajectory depends on continued execution of AI revenue growth and margin expansion targets.
Trailing returns across standard periods
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools (45% of fiscal 2021 sales), cross lab (35% of sales consisting of consumables and services related to its life science and applied tools), and diagnostics and genomics (20%). Over half of its sales are generated from the biopharmaceutical, chemical, and energy end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. (34%) and China (20%) representing the largest country concentrations.
Read more on A →Five9 provides cloud-native contact center software that enables digital customer service, sales, and marketing engagement. The company's Virtual Contact Center platform combines core telephony functionality, omnichannel engagement capabilities, and various software modules into a unified cloud contact-center-as-a-service, or CCaaS, platform. Five9's artificial intelligence and automation portfolio supplements and enhances the firm's core CCaaS offerings, including solutions for digital self-service, agent assist technology, and workflow automation. Five9 also offers workforce optimization products that optimize call center efficiency through workforce management solutions, manage interaction quality, and track agent performance.
Read more on FIVN →